42.93
1.29%
-0.56
Pre-market:
44.00
1.07
+2.49%
Merus N V stock is traded at $42.93, with a volume of 599.10K.
It is down -1.29% in the last 24 hours and down -18.52% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$43.49
Open:
$43.3
24h Volume:
599.10K
Relative Volume:
1.30
Market Cap:
$2.94B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-11.42
EPS:
-3.76
Net Cash Flow:
$-157.31M
1W Performance:
-15.71%
1M Performance:
-18.52%
6M Performance:
-1.60%
1Y Performance:
+76.67%
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
MRUS | 42.93 | 2.94B | 35.93M | -244.56M | -157.31M | -3.76 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Merus N V Stock (MRUS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-02-23 | Initiated | Canaccord Genuity | Buy |
Aug-21-23 | Initiated | TD Cowen | Outperform |
Aug-02-22 | Initiated | Stifel | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Feb-10-22 | Initiated | Needham | Buy |
Nov-17-21 | Resumed | Guggenheim | Buy |
Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
Apr-08-21 | Initiated | William Blair | Outperform |
Mar-16-21 | Initiated | SVB Leerink | Outperform |
Jun-26-20 | Initiated | H.C. Wainwright | Buy |
May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-20-19 | Resumed | Guggenheim | Buy |
Jun-28-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Resumed | Guggenheim | Buy |
Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-27-19 | Initiated | Berenberg | Buy |
Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
Jun-13-16 | Initiated | Citigroup | Buy |
Jun-13-16 | Initiated | Guggenheim | Buy |
Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus initiated with a Buy at Goldman Sachs - TipRanks
Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat
37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World
Merus is Now Oversold (MRUS) - Nasdaq
GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat
2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World
Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com
SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com
(MRUS) Trading Report - Stock Traders Daily
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN
FMR LLC Bolsters Stake in Merus NV - GuruFocus.com
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat
US FDA extends review of Merus' gene-targeting cancer therapy - MSN
Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat
MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan
Merus to Present at Upcoming Investor Conferences - The Manila Times
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada
FDA extends review date for Merus' cancer drug Zeno - Investing.com India
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com India
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus says FDA extended review period for cancer drug - MSN
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada
Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):